Luminex Plc · CSELK:LUMX.N0000
Luminex — J.P. Morgan 38th Annual Healthcare Conference (January 2020)
24 slides from Luminex's conference presentation, Jan 13, 2020
Slide 1: J.P. Morgan 38th Annual Healthcare Conference Investor Presentation
J.P. MORGAN 38TH ANNUAL HEALTHCARE CONFERENCE INVESTOR PRESENTATION Homi Shamir, President and CEO
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our
Slide 3: Overview
OVERVIEW MOLECULAR LIFE SCIENCE & DIAGNOSTICS CLINICAL TOOLS (MDx) (Tools) LICENSED FLOW TECHNOLOGIES AUTOMATED NON-AUTOMATED CYTOMETRY GROUP (LTG) complexity simplified. Recurring revenue items 3
Slide 4: Overview: 2019 revenue by segment
OVERVIEW 2019 Note: all figures approximate $335M M Dx TOOLS $137M $194M LICENSED FLOW TECHNOLOGIES AUTOMATED NON-AUTOMATED CYTOMETRY GROUP (LTG) $76M $61M $149M $45M complexity simplified. Recurring revenue items 4
Slide 5: Innovation, Execution, New Products: Significant Revenue Increase
INNOVATION, EXECUTION, NEW PRODUCTS SIGNIFICANT REVENUE INCREASE: $227M TO $335M FROM 2014 TO 2019, 8% REVENUE CAGR 11% REVENUE CAGR (Ex-LabCorp) VERIGENE® II GI FDA Submission ARIES® 7 FDA Clearances Flow Cytometry Acquisition Nanosphere Acquisition Homi Shamir joins Luminex as CEO NOV 2019 2015- 2
Slide 6: Innovative Pipeline: New Product Launches Drive Revenues
INNOVATION, EXECUTION, NEW PRODUCTS Innovative Pipeline $500M NEW PRODUCT LAUNCHES DRIVE REVENUES FROM ~$335 TO $500M BY 2024 Guava Next Gen System 2021 & “SENSIPLEX™” BEYOND VERIGENE® II 2020 2020 2020 complexity simplified. 6
Slide 7: Highlights of Our Business
HIGHLIGHTS OF OUR BUSINESS 7
Slide 8: Molecular Diagnostics - Sample to Answer
MOLECULAR DIAGNOSTICS - SAMPLE TO ANSWER (S2A) DISTINCTIVE DIAGNOSTIC SOLUTIONS DELIVER 20% CUSTOMER GROWTH CAGR VERIGENE® S2A ACTIVE CUSTOMERS ARIES® $122,000 660 $57,000 Avg Annual Revenue/Active Customer* Avg Annual Revenue/Active Customer* Syndromic Assays: Targeted Assays: BC-GN, BC-GP, EP, RP
Slide 9: Licensed Technologies Group
LICENSED TECHNOLOGIES GROUP 17,000 CUMULATIVE ® CONSISTENT MID-SINGLE-DIGIT GROWTH, XMAP SYSTEMS HIGHLY PROFITABLE, LONG-TERM PARTNERSHIPS SOLD TO DATE LTG - R E L A T E D % OF TOTAL LTG - R E L A T E D REVENUE, BY TYPE REVENUE, BY MARKET 17,000 14,900 12,700 10,700 35% 8,700 14% 30 % 50 % 20 20% 31
Slide 10: Flow Cytometry Portfolio
FLOW CYTOMETRY PORTFOLIO BALANCE OF PERFORMANCE AND AFFORDABILITY IN ATTRACTIVE GROWTH MARKETS Muse® easyCyte™ CellStream® FlowSight® ImageStream®X easyCyte™ HT Mk II Cell Count, Viability, Advanced Phenotyping Cell Function & Cell Health, Phenotype Phenotyping & Analysis Mechanism PERFORMANCE PERFO
Slide 11: Valued New Products
VALUED NEW PRODUCTS 11
Slide 12: New and Transformative Era for Luminex
NEW AND TRANSFORMATIVE ERA FOR LUMINEX ANTICIPATED LAUNCHING 3 NEW PLATFORMS IN 2020 1 VERIGENE® II ‒ Flexibility like never before ‒ Launch in mid-2020 2 “SENSIPLEX™” ‒ Modern enhancements for the gold standard multiplexing platform ‒ Launch in mid-2020 3 NEXT GEN GUAVA easyCYTE™ SYSTEM ‒ Flexible.
Slide 13: VERIGENE II Relative to VERIGENE I
VERIGENE® II RELATIVE TO VERIGENE® I FLEX® TESTING, FULLY AUTOMATED, AND ADDITIONAL BENEFITS IN VERIGENE® II VERIGENE® I VERIGENE® II THROUGHPUT Fixed: 1 Test Flexible: 1-6 Manual Set-up and Fully Automated: Sample to Result AUTOMATION LEVEL Transfer to Reader (Simplify and Reduce Training) FLEX CAP
Slide 14: VERIGENE II: Flexibility Like Never Before
VERIGENE® II: FLEXIBILITY LIKE NEVER BEFORE FLEX® TESTING: CUSTOMERS PAY ONLY FOR TARGETS THEY SELECT USERS CHOOSE TO BE FULL PANEL OR FLEX CUSTOMERS PRIOR TO INSTALLATION ‒ Full panel customers view all targets, every time, at a fixed cost ‒ Flex customers view fewer targets at a reduced cost, but
Slide 15: Flex Testing and Reimbursement Strategy
REIMBURSEMENT FLEX® TESTING IS FLEX TESTING UPDATES STRATEGY HELPS CUSTOMERS IDEAL FOR MAXIMIZE THEIR REIMBURSEMENT PROFITABILITY LANDSCAPE OPTIMIZING FLEX TESTING: CODING STRATEGY FLEX TESTING HELPS CUSTOMERS HELPS LABS OPTIMIZE PANELS FAVORED MAXIMIZE THEIR BY MOST RECENT REIMBURSEMENT TEST QUALIT
Slide 16: Newest Member of the xMAP System Family
INTRODUCING THE NEWEST MEMBER OF THE xMAP® SYSTEM FAMILY MODERN ENHANCEMENTS FOR THE GOLD STANDARD MULTIPLEXING PLATFORM ® • 500-plex “SENSIPLEX™” System • 20 min read time FLEXMAP 3D FLEXMAP • Full xMAP backwards-compatibility • Increased sensitivity & dynamic range 200™ ® 100-plex • • Improved aut
Slide 17: Innovations in Flow Cytometry
INNOVATIONS IN FLOW CYTOMETRY GUAVA® easyCYTE™ NEXT GENERATION STRENGTHENING GUAVA’S POSITION IN BENCHTOP FC IMAGESTREAM® x (ISX) NEXT GENERATION TURNING ISX INTO A MAINSTREAM INSTRUMENT • Accessible to novice image flow users MACHINE LEARNING & IDEAS SOFTWARE! • Image-driven, hence no user ARTIFICI
Slide 18: Financial Overview
FINANCIAL OVERVIEW
Slide 19: Significant Growth in Revenue (Ex-LabCorp)
SIGNIFICANT GROWTH IN REVENUE (EX-LABCORP) DOUBLE-DIGIT INCREASE IN ORGANIC REVENUE GROWTH (EX-LABCORP) IN 2020; LABCORP REVENUE HEADWIND OF 2% TO 3% IN 2020 $5M $16M $352M CONSISTENT $47M $319M REVENUE GROWTH $61M EX-LABCORP $55M $268M $245M (incl. 2020 guidance) $56M $48M $215M $179M $182M 2014 20
Slide 20: 19% Total Revenue Growth in 2019
19% TOTAL REVENUE GROWTH IN 2019* Q4 2019 vs. prior year 2019 vs. prior year Revenue Sources: Revenue w/o LabCorp $34.3 +1% $121.2 +4% LabCorp Revenue* $4.5 -10% $15.5 -67% Total MDx Solutions Revenue $38.8 0% $136.7 -16% Flow Cytometry Revenue** $11.9 +2% $45.1 +11% LTG Revenue $38.6 -7% $149.1 0%
Slide 21: Revenue in 2019 and 2020; Long-Term Revenue Target $500M
REVENUE IN 2019 AND 2020 LONG-TERM REVENUE TARGET IS $500M FULL-YEAR 2019 • 19% total revenue growth (Ex-LabCorp revenue) • LTG: flat REVENUE • 6% total revenue growth (All LMNX) • Total MDx Solutions: -16% • ~$32M less LabCorp revenue • S2A: +22% $335M • Flow Cytometry: +11% FULL-YEAR 2020 • As we
Slide 22: Wrap-Up
Luminex. complexity simplified. WRAP-UP
Slide 23: Luminex Investment Highlights
LUMINEX INVESTMENT HIGHLIGHTS DIVERSIFIED PRODUCT SERVING MULTI-BILLION OFFERINGS DOLLAR MARKETS • Automated & Flexible MDx Solutions • Life Science Research – Targeted • Clinical Diagnostics – Syndromic • Non-Automated MDx Solutions • Life Science and Clinical Tools STRONG BALANCE SHEET Entering a
Slide 24: Thank You
Luminex. complexity simplified. THANK YOU
Luminex — J.P. Morgan 38th Annual Healthcare Conference (January 2020) on 6ix